These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29141648)

  • 1. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
    Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
    J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML).
    Zhu KW; Chen P; Zhang DY; Yan H; Liu H; Cen LN; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Chen XP
    J Transl Med; 2018 Apr; 16(1):90. PubMed ID: 29631596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
    Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
    J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients.
    Kim KI; Huh IS; Kim IW; Park T; Ahn KS; Yoon SS; Yoon JH; Oh JM
    Eur J Cancer; 2013 Jan; 49(2):403-10. PubMed ID: 22964418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
    Elsayed AH; Cao X; Mitra AK; Wu H; Raimondi S; Cogle C; Al-Mansour Z; Ribeiro RC; Gamis A; Kolb EA; Aplenc R; Alonzo TA; Meshinchi S; Rubnitz J; Pounds S; Lamba JK
    J Clin Oncol; 2022 Mar; 40(7):772-783. PubMed ID: 34990262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia.
    Wang B; Zhang J; Hua X; Li H; Wang Z; Yang B
    Sci Rep; 2020 Jan; 10(1):685. PubMed ID: 31959790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study.
    Wan H; Zhu J; Chen F; Xiao F; Huang H; Han X; Zhong L; Zhong H; Xu L; Ni B; Zhong J
    J Exp Clin Cancer Res; 2014 Nov; 33(1):90. PubMed ID: 25398670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
    Xu P; Zhou D; Ouyang J; Chen B
    Leuk Lymphoma; 2016; 57(4):921-6. PubMed ID: 26384082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.
    Xiao Q; Deng D; Li H; Ye F; Huang L; Zhang B; Ye B; Mo Z; Yang X; Liu Z
    Ann Hematol; 2014 Aug; 93(8):1381-90. PubMed ID: 24994605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy.
    Amaki J; Onizuka M; Ohmachi K; Aoyama Y; Hara R; Ichiki A; Kawai H; Sato A; Miyamoto M; Toyosaki M; Machida S; Kojima M; Shirasugi Y; Kawada H; Ogawa Y; Ando K
    Int J Hematol; 2015 Jun; 101(6):543-53. PubMed ID: 25735499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
    Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
    Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
    Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
    Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
    Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
    Chen P; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Chen XP
    J Transl Med; 2018 Jul; 16(1):197. PubMed ID: 30016963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
    Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
    Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
    Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
    Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
    Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.